BDX BECTON DICKINSON & CO Insider Trading

Director Hayes Gregory bought 5,250 shares of BDX at $191.57 on 2025-08-11, raising holdings to 6,046 shares (+659.5% increase).

Hayes Gregory, a director at Becton Dickinson, purchased 5,250 shares worth $1,005,742.50 in a substantial open-market transaction, increasing his position from 796 shares to 6,046 shares—a 659.5% increase. The purchase at $191.57 occurred while BDX traded within its 52-week range, currently at $192.50 and 30-day returns are positive at +9.4%. Gregory's cross-ticker track record shows a mixed history: his prior 6 sales averaged 5.0% returns over 30 days and 5.7% over 90 days, with a well-timed sell rate of 0.00%, indicating his prior sales did not precede stock declines. This new buy transaction materially expands his stake in a $55.2B-market-cap company with recent quarterly revenue of $5.5B and a P/E of 34.81, suggesting the director is committing incremental capital at near-recent levels.

Director Henderson buys 1,500 BDX shares for $350,430 at $233.62; holdings rise 23.0% to 8,015 shares

Director Jeffrey William Henderson purchased 1,500 shares of Becton Dickinson at $233.62 on 2025-02-10, expanding his post-transaction holdings to 8,015 shares, a 23.0% increase from his pre-transaction position of 6,515 shares. The buy occurred at a price $4.07 above the current market price of $229.55, and near the middle of the 52-week range of $220.02–$249.08. Becton Dickinson is a large-cap healthcare company ($65.9B market cap) with solid fundamentals: latest quarterly revenue of $5,168,000,000.00 and net income of $303,000,000.00, with annual revenue growth of +4.2%. The transaction represents a substantial capital commitment of $350,430.00 by a board-level insider and reflects accumulation activity in a diversified medical-device manufacturer during a period of modest positive fundamentals.

EVP Michael David sold 2,838 shares of BDX at $223.33; holdings drop 31.6% to 6,141 shares

Michael David, EVP & President Medical at Becton Dickinson, sold 2,838 shares on 2024-12-19 at $223.33, reducing his post-transaction holdings from 8,979 to 6,141 shares—a reduction of 31.6% of his prior holdings. The sale occurred at a price $4.35 below the current market price of $227.68, placing the transaction within recent trading activity but below the 52-week high of $247.73. With the company reporting 4.2% annual revenue growth and a P/E of 40.30, this is a material reduction in an executive's direct stake rather than a routine small-scale rebalancing. The magnitude of the holding reduction—nearly one-third—warrants investor attention to understand the business context and whether this reflects broader patterns among company leadership.

BDX EVP Roland Goette sells 5,121 shares (26.5% of holdings) at blended avg $220.76; prior same-ticker sells 80% well-timed at 90d.

Goette executed 2 separate sales on 2024-12-06 and 2024-12-09, reducing holdings from 19,338 to 14,217 shares (26.5% reduction). His cross-ticker track record shows 83.33% well-timed sells (90-day returns averaging -0.3%), and at BDX specifically, 4 of 5 prior trades were well-timed when measured at the 90-day mark. The blended sale price of $220.76 sits near the current price of $221.44 with the stock down 5.2% over 90 days from the sale dates, placing this transaction within the pattern of prior BDX sales that captured value ahead of subsequent declines. BDX's P/E of 39.19 and modest +4.2% revenue growth provide limited upside support at recent valuations.